Hormone

GLP-1Studienlage & Dosis

Glucagon-like Peptide 1 — Inkretin, Sättigung, Blutzucker, Semaglutid-Wirkmechanismus.

Studienlage in Zahlen

Studien gesamt: 1.000
Mit Abstract: 36
Meta / Systematic / RCT: 3
Häufig zitiert: 4
Erscheinungsjahre: 1986–2026

GLP-1 im Kontext von Hormone

Dieses Thema ist Teil unserer Welt „Hormone". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Hormone

Top-Studien zu GLP-1

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
Diabetes1994n=6200 einflussreiche Zitationen
Using specific radioimmunoassays, we studied the occurrence of amidated and glycine-extended glucagon-like peptide I (GLP-I) molecules in the human small intestine and pancreas and in the circulation system in response to a breakfast meal.…
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
Diabetes care199285 einflussreiche Zitationen
<h4>Objective</h4>Whether glucagonlike peptide-I-(7-37) (GLP-I-[7-37]), a naturally occurring intestinal peptide, is insulinotropic in nondiabetic and non-insulin-dependent (type II) diabetic subjects.<h4>Research design and…
Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.
Receptors & channels200229 einflussreiche Zitationen
The glucagon-like peptides include glucagon, GLP-1, and GLP-2, and exert diverse actions on nutrient intake, gastrointestinal motility, islet hormone secretion, cell proliferation and apoptosis, nutrient absorption, and nutrient…
Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.
Neuroscience research20069 einflussreiche Zitationen
Glia play an important role in neurotoxicity in neurodegenerative diseases. In this study, we investigated the expression of glucagon-like peptide-1 (GLP-1) and its receptor, and the effects of GLP-1 on lipopolysaccharide (LPS)-induced…
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Lancet Diabetes Endocrinol2025n=623RCT4 einflussreiche Zitationen
<h4>Background</h4>Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide,…
GLP-1, a powerful physiological incretin: an update.
J Biol Regul Homeost Agents2018Systematic Review2 einflussreiche Zitationen
Food intake, especially carbohydrates, release incretin, which is an endocrine transmitter. Among the various endocrine modulators, Glucagon-like peptide 1 (GLP-1) is more effective in stimulating the release of insulin and more powerful…
Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor With Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement
The American Journal of Cardiology20262 einflussreiche Zitationen
Aortic valve disease is the most common valvular disease and is often seen in the elderly population. Transcatheter aortic valve replacement (TAVR) is a favorable and rapidly evolving intervention. Despite highly effective procedural…
Glucagon-like peptides.
Diabetes19981 einflussreiche Zitationen
Proglucagon contains the sequence of two glucagon-like peptides, GLP-1 and GLP-2, secreted from enteroendocrine cells of the small and large intestine. GLP-1 lowers blood glucose in both NIDDM and IDDM patients and may be therapeutically…
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Clinical Microbiology and Infection20261 einflussreiche Zitationen
<h4>Background</h4>Patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose co-transporter 2 (SGLT2) inhibitors often have underlying conditions that predispose them to infection. While these agents offer…
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Journal of Advanced Research20261 einflussreiche Zitationen
<h4>Background</h4>Musculoskeletal diseases (MSDs) are prevalent health problems that have a chronic course and are closely related to metabolic disorders. Several incretins, including glucose-dependent insulinotropic polypeptide (GIP) and…